(VALN) Valneva SE Business Model Canvas Research

Valneva SE uses local commercial distributors to sell in the United States, Canada, Germany, Austria, the Nordic countries, the United Kingdom, other European markets, and abroad. This setup fits a fragmented travel vaccine market and broadens coverage without building a full sales force in every country.

• Reaches 8 selling regions
• Cuts direct sales cost
• Scales in local markets

Valneva SE depends on a clinical and regulatory network of trial sites, investigators, and health authorities to run Phase II and Phase III studies and secure market approvals. In 2024, Valneva reported €173.0 million in total revenue and €87.6 million in R&D spending, showing how central these partnerships are to moving vaccine candidates from data to sales.

• Runs Phase II and Phase III studies
• Supports approvals with regulators
• Turns candidates into marketed vaccines

Valneva SE runs regulatory and market access work across Europe, North America, and other jurisdictions, preparing filings, approvals, and lifecycle updates for marketed vaccines and pipeline assets. This is core to keeping products on market in 20+ countries and moving candidates through agencies such as EMA and FDA.

• Supports sales of approved products
• Drives pipeline approval steps
• Manages country-by-country filings

Valneva SE’s commercial sales and distribution keep IXIARO and DUKORAL available across key markets through market support, channel management, and supply planning. In 2024, Valneva reported product sales of €153.4 million, with IXIARO and DUKORAL as the main commercial travel vaccine brands.

• Multi-geo vaccine access
• Channel and supply control
• Supports traveler demand

Valneva SE’s key resource is its vaccine know-how: Vero cell culture and oral vaccine development. This platform underpins 3 marketed vaccines and supports future candidates, while Vero-based manufacturing is a hard-to-copy capability that raises entry barriers.

• Vero cell culture expertise
• Oral vaccine development know-how
• Supports 3 marketed vaccines
• Creates high entry barriers

Valneva SE was founded in 1998 and is headquartered in Saint-Herblain, France. Its specialist biopharmaceutical team is a core resource because it supports R and D, regulatory work, manufacturing, and commercialization across the vaccine pipeline.

• Founded in 1998
• Headquarters: Saint-Herblain, France
• Human capital drives R and D
• Also supports regulatory and manufacturing

VLA1553 is Valneva SE’s single-shot chikungunya vaccine, backed by Phase III data showing a 98.8% seroresponse at Day 28. A one-dose profile can cut follow-up visits and simplify rollout, which matters for public-health use in outbreak regions.

• Single-dose, easier logistics
• Phase III, 98.8% Day 28 seroresponse
• Built for outbreak response

Valneva SE’s portfolio pairs 3 marketed vaccines with late-stage candidates, covering Japanese encephalitis, cholera, chikungunya, Lyme disease, ETEC, and COVID-19. That mix keeps the value proposition tied to travel medicine and endemic infection prevention, where demand is driven by real-world exposure and vaccination need, not broad consumer cycles.

• 3 approved vaccines today
• 6 disease areas covered
• Travel and endemic focus

Valneva SE sells vaccines through institutional procurement, where public health systems, clinics, and distributors place bulk orders under organized buying channels. This model supports repeat supply and wider market access; Valneva reported total revenue of €169.6 million in 2024, showing how institutional demand anchors sales.

• Bulk buying by health systems
• Repeat orders from clinics and distributors

Valneva SE relies on partner co-development relationships with Pfizer and Instituto Butantan to move key vaccines through long cycles of joint planning, data sharing, and launch alignment. These ties are central to its pipeline: Pfizer is advancing VLA15 in Phase 3 Lyme disease development, while Instituto Butantan supports chikungunya vaccine access in Brazil.

• Two core long-term partners
• Shared R&D and regulatory work
• Commercial plans linked to pipeline

Valneva SE uses physicians, pharmacies, hospitals, and clinics to let vaccines be prescribed or given under local rules, which helps reach both routine and at-risk patients across different health systems. This channel mix supports products like IXIARO, sold in more than 40 countries, by widening access beyond one care setting.

• Pharmacies boost easy adult access
• Hospitals reach higher-risk patients
• Local rules shape who can vaccinate

Pfizer and Instituto Butantan extend Valneva SE’s commercialization reach for pipeline assets, so Valneva SE can tap Pfizer’s global vaccine sales network and Instituto Butantan’s Brazil and Latin America access without building every local channel itself. This partner-led model lowers go-to-market load and speeds scale for assets like VLA15 and chikungunya programs.

• Pfizer adds global market access.
• Instituto Butantan opens Brazil.
• Valneva SE reduces channel build costs.

Retail pharmacies, hospital systems, and private clinics are key last-mile buyers for Valneva SE, because they expand vaccine access beyond public hospitals and make routine administration easier for adult and travel immunization. In countries with broad pharmacy vaccination rights, this channel can speed uptake and lift repeat demand.

• Pharmacies add convenience
• Clinics support routine access
• Hospitals cover higher-acuity sites

Valneva SE targets at-risk populations whose need is driven by exposure to region-specific disease threats, not by one fixed demographic. Depending on the product label and local guidance, this can include adults and children; for example, IXIARO is approved for ages 2 months and older in some markets, so the segment shifts with travel, outbreak, and endemic-risk patterns.

• Exposure risk drives demand
• Adults and children may qualify
• Label and local guidance matter

Valneva SE’s sales, marketing and distribution costs are tied to getting commercial vaccines into doctors’ offices, pharmacies, and public programs, with promotion and market-access work rising as the product mix expands. Multi-country rollouts add transport and storage costs, especially for temperature-controlled vaccines, so these expenses scale with geographic reach and launch count.

• Market access drives spend
• Cold-chain logistics add cost
• More countries, higher distribution load

Valneva’s general administration cost sits in its France headquarters and global coordination, and it rises when the Company supports Pfizer and Instituto Butantan. In 2025, this also includes regulatory and legal work tied to vaccine partnerships and market access.

• France HQ overhead

• Partnership management cost

• Regulatory and legal support

Instituto Butantan collaboration revenue from VLA1553 can come from development, manufacturing, and marketing work, plus milestone payments and any shared commercial upside. For Valneva SE, this helps fund the chikungunya vaccine, which already won U.S. FDA approval in 2023 as a single-dose product, while lowering the cost and execution load of going alone.

• Revenue tied to development work
• Can include milestones and shared sales
• Reduces solo launch burden

Valneva SE earns revenue from vaccine sales across the United States, Canada, Germany, Austria, the Nordic countries, the United Kingdom, and other European markets, so no single country drives the whole top line. That spread matters in 2025 because it cuts dependence on one national payer or tender cycle and can smooth demand swings.

• Sales span 7 named markets plus Europe
• Lower reliance on one country
• Broader reach supports steadier revenue